Identification and Management of High Risk Patients with Hypertrophic Cardiomyopathy

  • P. M. Elliott
  • W. J. McKenna
Conference paper


Hypertrophic cardiomyopathy (HCM) is a primary heart muscle disorder caused by mutations in genes encoding cardiac sarcomeric proteins. The pathological hallmarks of the disease, namely myocardial hypertrophy, myocyte disarray and fibrosis, result in a diverse pathophysiology that includes myocardial ischaemia, diastolic dysfunction, ventricular and atrial arrhythmia, and congestive cardiac failure [1]. While it has been long recognised that sudden death is a complication of the disease, the identification and treatment of patients at risk of dying suddenly remains a contentious issue.


Heart Rate Variability Sudden Death Hypertrophic Cardiomyopathy Familial Hypertrophic Cardiomyopathy Trophic Cardiomyopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775–785PubMedCrossRefGoogle Scholar
  2. 2.
    Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, Takikawa R, Hasegawa I, Takahashi T, Suzuki J-I, Sugimoto T, Saito K-I (1987) Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 59:183–184PubMedCrossRefGoogle Scholar
  3. 3.
    Savage DD, Castelli WP, Abbott RD, Garrison RJ, Anderson SJ, Kanell WB, Feinleib M (1983) Hypertrophic cardiomyopathy and its markers in the general population: the great masquerader revisited: the Framingham Study. J Cardiovasc Ultrason 2:41–47Google Scholar
  4. 4.
    Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophie cardiomyopathy in a population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary Artery Risk Development in (Young) Adults. Circulation 92:785–789Google Scholar
  5. 5.
    Codd MB, Sugrue DD, Gersh BJ, Melton LJ (1989) Epidemiology of idiopathic dilated and hypertrophie cardiomyopathy: a population based study in Olmsted County, Minnesota, 1975–1984. Circulation 80:564–572PubMedCrossRefGoogle Scholar
  6. 6.
    Maron BJ, Peterson EE, Maron MS, Peterson JE (1994) Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol 73:577–580PubMedCrossRefGoogle Scholar
  7. 7.
    Maron BJ, Spirito P, Wesley Y, Arce J (1986) Development or progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy: identification by twodimensional echocardiography. N Engl J Med 315:610–614PubMedCrossRefGoogle Scholar
  8. 8.
    Topol EJ, Traill TA, Fortuin NJ (1985) Hypertensive hypertrophie cardiomyopathy of the elderly. N Engl J Med 312:277–283PubMedCrossRefGoogle Scholar
  9. 9.
    Fay WP, Taliercio CP, Ilstrup DM, Tajik AJ, Gersh BJ (1990) Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol 16:821–826PubMedCrossRefGoogle Scholar
  10. 10.
    Lewis JF, Maron BJ (1994) Clinical and morphology expression of hypertrophie cardiomyopathy in patients ≥ 65 years of age. Am J Cardiol 73:1105–1111PubMedCrossRefGoogle Scholar
  11. 11.
    Spirito P, Maron BJ, Bonow RO, Epstein SE (1987) Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophie cardiomyopathy. Am J Cardiol 60:123–129PubMedCrossRefGoogle Scholar
  12. 12.
    McKenna WJ, Deanfield J, Faruqui A, England D, Oakley C and Goodwin J (1981) Prognosis in hypertrophie cardiomyopathy. Role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 47:532–538Google Scholar
  13. 13.
    Spirito P, Chiarella F, Carratino L, Zoni-Berisso M, Bellotti P, Vecchio C (1989) Clinical course and prognosis of hypertrophie cardiomyopathy in an outpatient population. N Engl J Med 320:749–755PubMedCrossRefGoogle Scholar
  14. 14.
    Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ (1995) Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population. J Am Coll Cardiol 26:1529–1536PubMedCrossRefGoogle Scholar
  15. 15.
    McKenna WJ, Franklin RCG, Nihoyannopoulos P, Robinson KC, Deanfield JE (1988) Arrhythmia and prognosis in infants, children and adolescents with hypertrophie cardiomyopathy. J Am Coll Cardiol 11:147–153PubMedCrossRefGoogle Scholar
  16. 16.
    McKenna WJ, Deanfield JE (1984) Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Childhood 59:971–975CrossRefGoogle Scholar
  17. 17.
    Maron BJ, Tajik AJ, Ruttenberg HD, Graham TP, Atwood GF, Victorica BE, Lie JT, Roberts WC (1982) Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 65:7–17PubMedCrossRefGoogle Scholar
  18. 18.
    Jarcho JA, McKenna WJ, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, Donis Keller H, Seidman JG, Seidman CE (1989) Mapping a gene for familial hypertrophie cardiomyopathy to chromosome 14q 1. N Engl J Med 321:1372–1378PubMedCrossRefGoogle Scholar
  19. 19.
    Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna WJ, Vosberg HP, Seidman JG, Seidman CE (1994) Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophie cardiomyopathy: a disease of the sarcomere. Cell 77:701–712PubMedCrossRefGoogle Scholar
  20. 20.
    Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, Labeit S, James M, Beckmann J et al (1995) Cardiac myosin binding protein C gene splice acceptor site mutation is associated with familial hypertrophie cardiomyopathy. Nature Genetics 11:438–440PubMedCrossRefGoogle Scholar
  21. 21.
    Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, Sellers JR, Fananapazir L, Epstein ND (1996) Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nature Genetics 13:63–69PubMedCrossRefGoogle Scholar
  22. 22.
    MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, Anan R, Thierfelder LH, McGarry K, Rowland E et al (1995) Familial hypertrophie cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 96:1216–1220PubMedCrossRefGoogle Scholar
  23. 23.
    Watkins H, Rosenzweig A, Hwang D, Levi T, McKenna W, Seidman CE, Seidman JG (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophie cardiomyopathy. N Engl J Med 326:1108–1114PubMedCrossRefGoogle Scholar
  24. 24.
    Spirito P, Maron BJ (1990) Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophie cardiomyopathy. J Am Coll Cardiol 15:1521–1526PubMedCrossRefGoogle Scholar
  25. 25.
    Frenneaux MP, Counihan PJ., Caforio A, Chikamori T, McKenna WJ (1990) Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82:1995–2002PubMedCrossRefGoogle Scholar
  26. 26.
    Sadoul N, Prasad K, Slade AKB, Elliott PM, McKenna WJ (1997) Abnormal blood pressure response during exercise is an independent marker of sudden death in young patients with hypertrophic cardiomyopathy. Circulation (in press).Google Scholar
  27. 27.
    Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ (1991) Abnormal vascular responses to supine exercise in hypertrophie cardiomyopathy. Circulation 84:686–696PubMedCrossRefGoogle Scholar
  28. 28.
    McKenna WJ, England D, Doi Y, Deanfield JE, Oakley CM, Goodwin JF (1981) Arrhythmia in hypertrophie cardiomyopathy. 1. Influence on prognosis. Br Heart J 46:168–172Google Scholar
  29. 29.
    Maron BJ, Savage DD, Wolfson JK, Epstein SE (1981) Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophie cardiomyopathy: A prospective study. Am J Cardiol 48:252–257PubMedCrossRefGoogle Scholar
  30. 30.
    Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, Fragola PV, Chiarella F, Zoni-Berisso M, Branzi A et al (1994) Prognosis of asymptomatic patients with hypertrophie cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90:2743–2747PubMedCrossRefGoogle Scholar
  31. 31.
    Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki J, McKenna WJ (1990) Atrial fibrillation in hypertrophie cardiomyopathy: A longitudinal study. J Am Coll Cardiol 15:1279–1285PubMedCrossRefGoogle Scholar
  32. 32.
    Dritsas A, Sabarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM (1992) QT Interval abnormalities in hypertrophie cardiomyopathy. Clin Cardiol 15:739–742PubMedCrossRefGoogle Scholar
  33. 33.
    Yanagisawa-Miwa A, Inoue I, Sugimoto T (1991) Diurnal change in QT intervals in dilated and hypertrophie cardiomyopathy. Am J Cardiol 67:1428–1430PubMedCrossRefGoogle Scholar
  34. 34.
    Fei L, Slade AK, Grace AA, Malik M, Camm AJ, McKenna WJ (1994) Ambulatory assessment of the QT interval in patients with hypertrophie cardiomyopathy: risk stratification and effect of low dose amiodarone. Pacing and Clin Electrophys 17:2222–2227CrossRefGoogle Scholar
  35. 35.
    Buja G, Miorelli M, Turrini P, Melacini P, Nava A (1993) Comparison of QT dispersion in hypertrophie cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 72:973–976PubMedCrossRefGoogle Scholar
  36. 36.
    Kulakowski P, Counihan PJ, Camm AJ, McKenna WJ (1993) The value of time and frequency domain, and spectral temporal mapping analysis of the signal averaged electrocardiogram in identification of patients with hypertrophie cardiomyopathy at increased risk of sudden death. Eur Heart J 14:941–950PubMedCrossRefGoogle Scholar
  37. 37.
    Counihan PJ, Fei L, Bashir Y, Farrell TG, Haywood GA, McKenna WJ (1993) Assessment of heart rate variability in hypertrophie cardiomyopathy. Association with clinical and prognostic features. Circulation 88:1682–1690Google Scholar
  38. 38.
    Fananapazir L, Chang AC, Epstein SE, McAreavey D (1992) Prognostic determinants in hypertrophie cardiomyopathy: Prognostic evaluation of a therapeutic strategy based on clinical, holter, hemodynamic and electrophysiological findings. Circulation 86:730–740PubMedCrossRefGoogle Scholar
  39. 39.
    Kuck KH, Kunze KP, Schluter M, Nienaber CA, Costard A (1988) Programmed electrical stimulation in hypertrophie cardiomyopathy. Results in patients with and without cardiac arrest or syncope. Eur Heart J 92:177–185Google Scholar
  40. 40.
    Saumarez RC, Slade AKB, Grace AA, Sadoul N, Camm AJ, McKenna WJ (1995) The significance of paced electrocardiogram fractionation in hypertrophie cardiomyopathy. A prospective study. Circulation 91:2762–2768Google Scholar
  41. 41.
    Cecchi F, Maron BJ, Epstein SE (1989) Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 13:1283–1288PubMedCrossRefGoogle Scholar
  42. 42.
    McKenna WJ, Oakley CM, Krikler DM et al (1985) Improved survival with amiodarone in patients with hypertrophie cardiomyopathy and ventricular tachycardia. Br Heart J 53:412–416PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • P. M. Elliott
  • W. J. McKenna

There are no affiliations available

Personalised recommendations